Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021

Preclinical studies support the concept that inhibition of protein kinase C (PKC) by tamoxifen (TAM) should provide both antineoplastic effects and radiosensitization. High-dose TAM (80 mg/m(2) p.o. daily in divided doses) was given with and after conventional radiotherapy (XRT) to inhibit PKC-media...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Robins, H. Ian, Won, M., Seiferheld, Wendy F., Schultz, Christopher J., Choucair, Ali K., Brachman, David G., Demas, William F., Mehta, Minesh P.
Formato: Artigo
Idioma:Inglês
Publicado em: Duke University Press 2006
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1871929/
https://ncbi.nlm.nih.gov/pubmed/16443947
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1215/S1522851705000311
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados